Chromogranin-A-Derived Peptides and Periodontitis in Diabetic Patients

Periodontitis and Diabetitis Clinical Trial

Official title:

Chromogranin-A-Derived Peptides in the Gingival Crevicular Fluid and the Saliva of Diabetic Patients With or Without Periodontitis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00399620
• Other study ID #: 3739
• Status: Recruiting
• Phase: N/A
• First received: November 14, 2006
• Last updated: January 9, 2009
• Start date: March 2008

Study information

• Verified date: January 2009
• Source: University Hospital, Strasbourg, France
• Contact: Martine Soell, MD
• Phone: 33 6 74 86 67 36
• Email: martine.soell[@]chru-strasbourg.fr
• Is FDA regulated: No
• Health authority: France: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

Periodontitis is a chronic disease of the supporting tissue of the teeth, characterized by bleeding and inflamed gingival, resorption of alveolar bone. This disease has a significant impact of the quality of life as the teeth become progressively mobile and may fall out spontaneously if no treatment is provided. Periodontal disease has been cited as the sixth complication of diabetes mellitus.Chromogranins / secretogranins are a family of proteins present in nervous endocrine and immune cells, released with catecholamines during stress situations. Chromogranin A (CGA) is the major member of this family.The aim of this study is to determine the level of CGA and its derived peptides in the gingival crevicular fluid (GCF) of health or diabetic patients with and without periodontitis.Then, we want to determine the antimicrobial activity of these peptides.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 20 Years to 80 Years

Eligibility

Inclusion criteria:

• Patients from 20 to 80 years old

• A minimum of 10 teeth

• Healthy volunteers or diabetic patients with or without periodontitis

Exclusion criteria:

• a course of antibiotics

• a fungicidal therapy

• a corticotherapy

• a hormone therapy

• a pregnancy

• persons under guardianship

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Periodontitis
• Periodontitis and Diabetitis

Intervention

Procedure:
• Gingival crevicular fluid samples (this procedure is added to the subject usual medical follow-up).

Locations

Country	Name	City	State
France	Département de Parodontologie - Hôpital Civil	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France,